KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income towards Parent Company (2017 - 2025)

Historic Income towards Parent Company for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $18.1 million.

  • Amneal Pharmaceuticals' Income towards Parent Company rose 5422.3% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 13929.75%. This contributed to the annual value of -$73.9 million for FY2024, which is 5155.42% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Income towards Parent Company stood at $18.1 million for Q3 2025, which was up 5422.3% from $35.6 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Income towards Parent Company ranged from a high of $35.6 million in Q2 2025 and a low of -$240.1 million during Q2 2022
  • For the 5-year period, Amneal Pharmaceuticals' Income towards Parent Company averaged around -$14.7 million, with its median value being -$2.4 million (2022).
  • Over the last 5 years, Amneal Pharmaceuticals' Income towards Parent Company had its largest YoY gain of 113541.32% in 2023, and its largest YoY loss of 149508.11% in 2023.
  • Amneal Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$20.4 million in 2021, then soared by 71.33% to -$5.9 million in 2022, then plummeted by 1495.08% to -$93.4 million in 2023, then surged by 77.75% to -$20.8 million in 2024, then soared by 187.26% to $18.1 million in 2025.
  • Its last three reported values are $18.1 million in Q3 2025, $35.6 million for Q2 2025, and $24.6 million during Q1 2025.